Michael T Schweizer
Overview
Explore the profile of Michael T Schweizer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
2207
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raychaudhuri R, Tuchayi A, Low S, Arafa A, Graham L, Gulati R, et al.
Eur Urol Oncol
. 2025 Feb;
PMID: 39920014
Background And Objective: The prostate-specific membrane antigen (PSMA) radioligand Lu-PSMA-617 (LuPSMA) is approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). PARP inhibitors (PARPi) are approved for patients with mCRPC...
2.
Demirci R, Ghodsi A, Gulati R, Behnia S, Nelson P, Cheng H, et al.
J Nucl Med
. 2024 Nov;
66(1):47-53.
PMID: 39542703
The VISION and TheraP trials introduced different PET-based criteria for patient selection for treatment with Lu-PSMA-617 (LuPSMA). TheraP used a higher prostate-specific membrane antigen (PSMA) uptake threshold than VISION and...
3.
Demirci R, Gulati R, Hawley J, Yezefski T, Haffner M, Cheng H, et al.
J Nucl Med
. 2024 Nov;
65(12):1945-1951.
PMID: 39510589
Lu-PSMA-617 (LuPSMA) is a newly established treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), but survival outcomes vary widely, and predictors of treatment responses are needed. This study investigated...
4.
Graham L, Henderson N, Kellezi O, Hwang C, Barata P, Bilen M, et al.
JCO Precis Oncol
. 2024 Aug;
8:e2400014.
PMID: 39178368
Purpose: Outcomes data for DNA-damaging therapeutics for men with prostate cancer (PC) and non- homologous recombination repair (HRR) mutations are limited. We evaluated outcomes by HRR alteration in men with...
5.
Buxton C, Schmeusser B, Holt S, Patil D, Phuong A, Chahine S, et al.
Urology
. 2024 Jun;
192:74-82.
PMID: 38906271
Objective: To characterize changes in body composition following cytotoxic chemotherapy for germ cell carcinoma of the testis (GCT) and quantify associations between body composition metrics and chemotherapy-associated adverse events (AEs)...
6.
Raychaudhuri R, DeJong M, Rettig M, Yu E, Gulati R, Schweizer M, et al.
Eur Urol
. 2024 Jun;
87(3):375-376.
PMID: 38890069
No abstract available.
7.
Ajkunic A, Sayar E, Roudier M, Patel R, Coleman I, De Sarkar N, et al.
NPJ Precis Oncol
. 2024 May;
8(1):104.
PMID: 38760413
Therapeutic approaches targeting proteins on the surface of cancer cells have emerged as an important strategy for precision oncology. To capitalize on the potential impact of drugs targeting surface proteins,...
8.
Raychaudhuri R, Mo G, Tuchayi A, Graham L, Gulati R, Pritchard C, et al.
JCO Precis Oncol
. 2024 Apr;
8:e2300634.
PMID: 38662984
Purpose: While Lu-PSMA-617 (LuPSMA) is an effective therapy for many patients with metastatic castration-resistant prostate cancer (mCRPC), biomarkers associated with outcomes are not well defined. We hypothesized that prostate cancer...
9.
Park J, Chu A, Li J, Ali A, McKay R, Hwang C, et al.
JCO Precis Oncol
. 2024 Apr;
8:e2300567.
PMID: 38579192
Purpose: There are limited data available on the real-world patterns of molecular testing in men with advanced prostate cancer. We thus sought to evaluate next-generation sequencing (NGS) testing in the...
10.
Agarwal N, Castellano D, Alonso-Gordoa T, Arranz Arija J, Colomba E, Gravis G, et al.
Clin Cancer Res
. 2024 Mar;
30(11):2377-2383.
PMID: 38512117
Purpose: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors radically changed the treatment paradigm for breast cancer. Similar to estrogen receptor in breast cancer, androgen receptor signaling activates cyclin D-CDK4/6, driving...